Comparison of cefamandole, cephalothin, ampicillin, and chloramphenicol in experimental Escherichia coli meningitis.

Antimicrobial Agents and Chemotherapy
T R Beam, J C Allen

Abstract

The activities of cefamandole, cephalothin, ampicillin, and chloramphenicol were compared in fulminant and temperate Escherichia coli meningitis in rabbits. Intensive dosing schedules were employed to achieve maximal therapeutic benefits with short-term treatment. In an 8-h schedule chloramphenicol was significantly more effective in sterilizing the cerebrospinal fluid and curing both fulminant and temperate infections than cefamandole or ampicillin. Cephalothin was without effect in fulminant meningitis. Cefamandole and ampicillin were equivalent in activity in this and longer (12- and 24-hr) treatment schedules. The therapeutic benefits of chloramphenicol were purchased via use of doses above those generally regarded as safe for human use. The mean serum, cerebrospinal fluid, and brain concentrations of chloramphenicol, cefamandole, and ampicillin were significantly greater in rabbits with fulminant meningitis than in those with temperate meningitis. The difference was of such magnitude as to support the need to monitor drug concentrations.

References

May 1, 1975·Annals of Internal Medicine·L S FisherL B Guze
Feb 1, 1977·The Journal of Infectious Diseases·L J StrausbaughM A Sande
May 1, 1978·The Journal of Infectious Diseases·E A SteinbergJ M Leedom
May 1, 1979·Antimicrobial Agents and Chemotherapy·J R KoupR L Slaughter
May 1, 1978·The Journal of Infectious Diseases·O M KorzeniowskiM A Sande
Sep 1, 1978·Antimicrobial Agents and Chemotherapy·J R KoupT R Beam
Oct 1, 1976·The Journal of Clinical Investigation·S ShawD H Smith
Sep 1, 1969·Journal of Neurosurgery·P W KramerR L Campbell
Jun 1, 1972·American Journal of Diseases of Children·G H McCracken

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.